Phase II clinical trial of cabozantinib for the treatment of recurrent hepatocellular carcinoma after liver transplantation
Amirhossein Azhie(University Health Network), Mamatha Bhat(University Health Network), Lisa Wang(University of Toronto), Jennifer J. Knox(National Cancer Center), Robert C. Grant(Princess Margaret Cancer Centre), Michael Herman(Borland Groover Clinic)
Cited by 3
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma
|Journal of Clinical Oncology|2013|830
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial
|Clinical Cancer Research|2017|635
Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
|Journal of Clinical Oncology|2008|597